LP
CCCC icon

LMR Partners’s C4 Therapeutics CCCC Stock Holding History

LMR Partners’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-51,000
Closed -$184K – 1396
2024
Q4 		$184K Hold
51,000
– – ﹤0.01% 957
2024
Q3 		$291K Buy
+51,000
New +$307K ﹤0.01% 921
2024
Q2 		– Sell
-19,563
Closed -$160K – 1125
2024
Q1 		$160K Buy
+19,563
New +$152K ﹤0.01% 891

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

LMR Partners's CCCC Position: Q1 2025 in Review

LMR Partners sold out of C4 Therapeutics (CCCC) in Q1 2025, closing a stake of 51,000 shares — an estimated $184K sold.

LMR Partners first reported a position in CCCC in Q1 2024 and held it in 3 quarters. The position peaked at $291K in Q3 2024. 114 funds tracked by Wall St. Rank hold CCCC as of Q1 2025.

  • LMR Partners reported no remaining C4 Therapeutics position as of Q1 2025 after selling out during the quarter.
  • LMR Partners sold 51,000 C4 Therapeutics shares in Q1 2025, an estimated $184K.
  • LMR Partners first reported a position in C4 Therapeutics in Q1 2024 and held it in 3 quarters.
  • LMR Partners's C4 Therapeutics position peaked at $291K in Q3 2024.
  • 114 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.